Physician profile
Muhammad A Virk
NPI 1275845620
$7,659.45
in general payments reported to CMS, 2019-2025
34 companies · $2,217 in 2025
The $2,217 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.63 · 2021: $15.67 · 2022: $982 · 2023: $1,831 · 2024: $2,530 · 2025: $2,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,577.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,303.38 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $974.03 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $885.92 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $608.91 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.17 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Madrigal Pharmaceuticals | $384.24 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $383.60 | 2022-2025 | |
| Qol Medical, LLC | $268.65 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $247.01 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $220.56 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $176.71 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $171.48 | 2022-2025 | Ocaliva |
| Daiichi Sankyo INC. | $170.44 | 2023-2025 | Injectafer |
| Pfizer INC. | $167.58 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $147.17 | 2023-2024 | Rebyota |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $120.10 | 2022-2024 | Dificid |
| Celltrion USA INC. | $105.46 | 2024 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $95.74 | 2023 | Zeposia |
| Pharmacosmos Therapeutics INC. | $89.56 | 2024 | Monoferric |
| Evoke Pharma, INC. | $83.34 | 2023 | Gimoti |
| Astrazeneca Pharmaceuticals LP | $66.09 | 2019 | |
| Gilead Sciences, INC. | $61.47 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $59.49 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $58.62 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $53.93 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $53.40 | 2022-2023 | |
| Novo Nordisk INC | $51.82 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $51.62 | 2022 | |
| Boston Scientific Corporation | $33.21 | 2019-2021 | |
| Organon LLC | $28.58 | 2023 | Renflexis, Hadlima |
| Olympus America INC. | $18.66 | 2024 | Hanarostent Esophagus Tts(Ccc) |
| Albireo Pharma, INC. | $18.37 | 2023 | Bylvay |
| Shield Therapeutics INC | $15.40 | 2025 | |
| Fresenius Kabi USA, LLC | $12.74 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Virk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.